- Policy & Regulations
- 1 min read
China regulator fines two pharma firms for monopoly behaviour
The regulator fined Grand Pharmaceutical 136 million yuan ($19.68 million) and confiscated 149 million yuan of "illegal revenue" for entering into a monopolistic deal with Wuhan Healcare Pharmaceuticals.
Read by
It fined Grand Pharmaceutical 136 million yuan ($19.68 million) and confiscated 149 million yuan of "illegal revenue" for entering into a monopolistic deal with Wuhan Healcare Pharmaceuticals.
The regulator fined Wuhan Healcare Pharmaceuticals 4.13 million yuan and confiscated slightly over 30 million yuan of its revenue.
Since late 2020, Chinese regulators have started antitrust crackdowns on multiple industries, most notably on technology companies such as Alibaba Group.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions